Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Medtronic
Mallinckrodt
Colorcon
Express Scripts

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,696,178

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 7,696,178 protect, and when does it expire?

Patent 7,696,178 protects BETHKIS and is included in one NDA.

This patent has thirty-seven patent family members in twenty-six countries.

Summary for Patent: 7,696,178
Title:Optimised formulation of tobramycin for aerosolization
Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
Inventor(s): Malvolti; Chiara (Parma, IT), Garzia; Raffaella (Parma, IT)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:11/083,139
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,696,178
Patent Claim Types:
see list of patent claims
Formulation; Process;

Drugs Protected by US Patent 7,696,178

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi Usa Inc BETHKIS tobramycin SOLUTION;INHALATION 201820-001 Oct 12, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,696,178

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01116071Jul 02, 2001

International Family Members for US Patent 7,696,178

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 267591   Start Trial
Australia 2002319226   Start Trial
Bulgaria 108475   Start Trial
Bulgaria 66328   Start Trial
Brazil 0211320   Start Trial
Brazil PI0211320   Start Trial
Canada 2452638   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Harvard Business School
Medtronic
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.